Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Overcoming PARP inhibitor resistance in ovarian cancer: what are the most promising strategies?

Archives of gynecology and obstetrics - 1 Nov 2020

Klotz Daniel Martin, Wimberger Pauline

Abstract excerpt

PURPOSE: Ovarian cancer is the most lethal gynaecological malignancy. Despite the introduction of bevacizumab, standard chemotherapy has remained largely unchanged and the vast majority of patients will relapse within the first two years of diagnosis. However, results from recent clinical trials demonstrating clinical benefits of PARP inhibitor treatment are rapidly changing therapeutic options for many patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to BRCA1 Protein
Share to Carcinoma, Ovarian Epithelial

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Repair

Share to Mutation

Share to Neoplasm Recurrence, Local

Share to Ovarian Neoplasms

Share to Poly(ADP-ribose) Polymerase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 32833070
DOI: 10.1007/s00404-020-05677-1
PMCID: PMC7524817

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Overcoming PARP inhibitor resistance in ovarian cancer: what are the most promising strategies?PMID 32833070Read ↗

Treatment of Ovarian Cancer Beyond PARP Inhibition: Current and Future OptionsSemantic proximity Read ↗

PARP inhibitors: Clinical utility and possibilities of overcoming resistanceSemantic proximity Read ↗

Clinical Landscape of PARP Inhibitors in Ovarian Cancer: Molecular Mechanisms and Clues to Overcome ResistanceSemantic proximity Read ↗

Fighting resistance: post-PARP inhibitor treatment strategies in ovarian cancerSemantic proximity Read ↗

PARP Inhibitors in Ovarian Cancer: Resistance Mechanisms, Clinical Evidence, and Evolving StrategiesSemantic proximity Read ↗

A review on mechanisms of resistance to PARP inhibitorsSemantic proximity Read ↗

PARP Inhibitors for Ovarian Cancer: Current Indications, Future Combinations, and Novel Assets in Development to Target DNA Damage RepairSemantic proximity Read ↗

PARP Inhibitors in Breast and Ovarian CancerSemantic proximity Read ↗

Emerging strategies to overcome PARP inhibitors' resistance in ovarian cancerSemantic proximity Read ↗

PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancersSemantic proximity Read ↗

Overcoming resistance to PARP inhibitor in epithelial ovarian cancer, are we ready?Semantic proximity Read ↗

PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targetingSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.